Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Angiopoietin-2 (ANGPT2) is a secreted glycoprotein that serves as a key regulator of vascular remodeling and angiogenesis (UniProt: O15123). It primarily acts as a context-dependent antagonist of the Tie2 receptor tyrosine kinase, competing with the stabilizing ligand Angiopoietin-1 (ANGPT1) to promote vascular destabilization, which is necessary for vessel sprouting in the presence of VEGF (PubMed: 28611162). In pathological conditions such as cancer and neovascular eye diseases, ANGPT2 is frequently overexpressed, contributing to abnormal vessel growth, increased vascular permeability, and inflammation (PubMed: 31439490). Therapeutic strategies targeting ANGPT2, such as the bispecific antibody faricimab, aim to stabilize the vasculature and reduce pathological leakage by blocking ANGPT2-Tie2 signaling (DrugBank: DB15055). Additionally, ANGPT2 inhibition is being explored in oncology to normalize tumor vasculature and enhance the efficacy of other therapies (PubMed: 24501218).
Inhibition of ANGPT2 binding to the Tie2 receptor to prevent vascular destabilization and pathological angiogenesis (PubMed: 28611162).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Angiopoietin-2 (ANGPT2) (ANGPT2).